A patient in Japan with HIV began antiretroviral therapy because of acute hepatitis B virus (HBV) 15 years ago, with low hepatitis B surface antibody, and experienced breakthrough HBV reactivation 4 months after switching from bictegravir/emtricitabine/tenofovir alafenamide to cabotegravir/rilpivirine. An immune escape mutation, E164V, was identified in the isolated HBV DNA.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11286062 | PMC |
| http://dx.doi.org/10.3201/eid3008.240019 | DOI Listing |
Publication Analysis
Top Keywords
hepatitis virus
8
low hepatitis
8
hepatitis surface
8
surface antibody
8
hepatitis
4
virus reactivation
4
reactivation switch
4
switch cabotegravir/rilpivirine
4
cabotegravir/rilpivirine patient
4
patient low
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!